Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 85

1.

Correction to: Measuring and understanding adherence in a home-based exercise intervention during chemotherapy for early breast cancer.

Nyrop KA, Deal AM, Choi SK, Wagoner CW, Lee JT, Wood WA, Anders C, Carey LA, Dees EC, Jolly TA, Reeder-Hayes KE, Muss HB.

Breast Cancer Res Treat. 2018 Oct 11. doi: 10.1007/s10549-018-4975-8. [Epub ahead of print]

PMID:
30306432
2.

LCCC 1025: a phase II study of everolimus, trastuzumab, and vinorelbine to treat progressive HER2-positive breast cancer brain metastases.

Van Swearingen AED, Siegel MB, Deal AM, Sambade MJ, Hoyle A, Hayes DN, Jo H, Little P, Dees EC, Muss H, Jolly T, Zagar TM, Patel N, Miller CR, Parker JS, Smith JK, Fisher J, Shah N, Nabell L, Nanda R, Dillon P, Abramson V, Carey LA, Anders CK.

Breast Cancer Res Treat. 2018 Jun 25. doi: 10.1007/s10549-018-4852-5. [Epub ahead of print]

PMID:
29938395
3.

Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer.

Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE Jr, Dees EC, Goetz MP, Olson JA Jr, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Ravdin PM, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Berenberg JL, Abrams J, Sledge GW Jr.

N Engl J Med. 2018 Jul 12;379(2):111-121. doi: 10.1056/NEJMoa1804710. Epub 2018 Jun 3.

PMID:
29860917
4.

The incidence and predictive factors for leptomeningeal spread after stereotactic radiation for breast cancer brain metastases.

Kaidar-Person O, Deal AM, Anders CK, Ewend MG, Dees EC, Camporeale J, Ramirez J, Benbow JM, Marks LB, Zagar TM.

Breast J. 2018 May;24(3):424-425. doi: 10.1111/tbj.12919. Epub 2017 Dec 18. No abstract available.

PMID:
29251377
5.

A Phase I Trial of the PI3K Inhibitor Buparlisib Combined With Capecitabine in Patients With Metastatic Breast Cancer.

McRee AJ, Marcom PK, Moore DT, Zamboni WC, Kornblum ZA, Hu Z, Phipps R, Anders CK, Reeder-Hayes K, Carey LA, Weck KE, Perou CM, Dees EC.

Clin Breast Cancer. 2018 Aug;18(4):289-297. doi: 10.1016/j.clbc.2017.10.014. Epub 2017 Oct 28.

PMID:
29153866
6.

Measuring and understanding adherence in a home-based exercise intervention during chemotherapy for early breast cancer.

Nyrop KA, Deal AM, Choi SK, Wagoner CW, Lee JT, Wood A, Anders C, Carey LA, Dees EC, Jolly TA, Reeder-Hayes KE, Muss HB.

Breast Cancer Res Treat. 2018 Feb;168(1):43-55. doi: 10.1007/s10549-017-4565-1. Epub 2017 Nov 9. Erratum in: Breast Cancer Res Treat. 2018 Oct 11;:.

PMID:
29124455
7.

Aurora A Functional Single Nucleotide Polymorphism (SNP) Correlates With Clinical Outcome in Patients With Advanced Solid Tumors Treated With Alisertib, an Investigational Aurora A Kinase Inhibitor.

Niu H, Shin H, Gao F, Zhang J, Bahamon B, Danaee H, Melichar B, Schilder RJ, Coleman RL, Falchook G, Adenis A, Behbakht K, DeMichele A, Dees EC, Perez K, Matulonis U, Sawrycki P, Huebner D, Ecsedy J.

EBioMedicine. 2017 Nov;25:50-57. doi: 10.1016/j.ebiom.2017.10.015. Epub 2017 Oct 16.

8.

The effects of lapatinib on CYP3A metabolism of midazolam in patients with advanced cancer.

Koch KM, Dees EC, Coker SA, Reddy NJ, Gainer SD, Arya N, Beelen AP, Lewis LD.

Cancer Chemother Pharmacol. 2017 Dec;80(6):1141-1146. doi: 10.1007/s00280-017-3470-y. Epub 2017 Nov 2.

PMID:
29098381
9.

Changing Natural History of HER2-Positive Breast Cancer Metastatic to the Brain in the Era of New Targeted Therapies.

Mounsey LA, Deal AM, Keith KC, Benbow JM, Shachar SS, Zagar T, Dees EC, Carey LA, Ewend MG, Anders CK.

Clin Breast Cancer. 2018 Feb;18(1):29-37. doi: 10.1016/j.clbc.2017.07.017. Epub 2017 Aug 9.

10.

Informed Consent and Decision Making Among Participants in Novel-Design Phase I Oncology Trials.

Reeder-Hayes KE, Roberts MC, Henderson GE, Dees EC.

J Oncol Pract. 2017 Oct;13(10):e863-e873. doi: 10.1200/JOP.2017.021303. Epub 2017 Aug 24.

11.

Nanoparticle-Delivered Chemotherapy: Old Drugs in New Packages.

Lee MS, Dees EC, Wang AZ.

Oncology (Williston Park). 2017 Mar 15;31(3):198-208. Review.

12.

Phase I study of the gamma secretase inhibitor PF-03084014 in combination with docetaxel in patients with advanced triple-negative breast cancer.

Locatelli MA, Aftimos P, Dees EC, LoRusso PM, Pegram MD, Awada A, Huang B, Cesari R, Jiang Y, Shaik MN, Kern KA, Curigliano G.

Oncotarget. 2017 Jan 10;8(2):2320-2328. doi: 10.18632/oncotarget.13727.

13.

Ramucirumab With Eribulin Versus Eribulin in Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracycline and Taxane Therapy: A Multicenter, Randomized, Phase II Study.

Yardley DA, Reeves J, Dees EC, Osborne C, Paul D, Ademuyiwa F, Soliman H, Guthrie T, Andersen J, Krekow L, Choksi J, Daniel B, Danso M, Favret A, Oommen S, Brufsky A, Bromund JL, Lin Y, Ibrahim AB, Richards PD.

Clin Breast Cancer. 2016 Dec;16(6):471-479.e1. doi: 10.1016/j.clbc.2016.07.005. Epub 2016 Jul 29.

14.

Pharmacogenomics, Pharmacokinetics, and Pharmacodynamics in the Era of Targeted Therapies.

Calvo E, Walko C, Dees EC, Valenzuela B.

Am Soc Clin Oncol Educ Book. 2016;35:e175-84. doi: 10.14694/EDBK_159061. Review.

15.

Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study.

Nanda R, Chow LQ, Dees EC, Berger R, Gupta S, Geva R, Pusztai L, Pathiraja K, Aktan G, Cheng JD, Karantza V, Buisseret L.

J Clin Oncol. 2016 Jul 20;34(21):2460-7. doi: 10.1200/JCO.2015.64.8931. Epub 2016 May 2.

PMID:
27138582
16.

A Multidisciplinary Breast Cancer Brain Metastases Clinic: The University of North Carolina Experience.

McKee MJ, Keith K, Deal AM, Garrett AL, Wheless AA, Green RL, Benbow JM, Dees EC, Carey LA, Ewend MG, Anders CK, Zagar TM.

Oncologist. 2016 Jan;21(1):16-20. doi: 10.1634/theoncologist.2015-0328. Epub 2015 Dec 9.

17.

First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor Malignancies.

Munster P, Aggarwal R, Hong D, Schellens JH, van der Noll R, Specht J, Witteveen PO, Werner TL, Dees EC, Bergsland E, Agarwal N, Kleha JF, Durante M, Adams L, Smith DA, Lampkin TA, Morris SR, Kurzrock R.

Clin Cancer Res. 2016 Apr 15;22(8):1932-9. doi: 10.1158/1078-0432.CCR-15-1665. Epub 2015 Nov 24.

18.

Phase I Clinical Trials in Acute Myeloid Leukemia: 23-Year Experience From Cancer Therapy Evaluation Program of the National Cancer Institute.

Zeidner JF, Karp JE, Blackford AL, Foster MC, Dees EC, Smith G, Ivy SP, Harris P.

J Natl Cancer Inst. 2015 Nov 9;108(3). doi: 10.1093/jnci/djv335. Print 2016 Mar.

19.

Prospective Validation of a 21-Gene Expression Assay in Breast Cancer.

Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE Jr, Dees EC, Perez EA, Olson JA Jr, Zujewski J, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Ravdin P, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Atkins JN, Berenberg JL, Sledge GW.

N Engl J Med. 2015 Nov 19;373(21):2005-14. doi: 10.1056/NEJMoa1510764. Epub 2015 Sep 27.

20.

Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [18F]Fluorodeoxyglucose Positron Emission Tomography Imaging (TBCRC 003).

Lin NU, Guo H, Yap JT, Mayer IA, Falkson CI, Hobday TJ, Dees EC, Richardson AL, Nanda R, Rimawi MF, Ryabin N, Najita JS, Barry WT, Arteaga CL, Wolff AC, Krop IE, Winer EP, Van den Abbeele AD.

J Clin Oncol. 2015 Aug 20;33(24):2623-31. doi: 10.1200/JCO.2014.60.0353. Epub 2015 Jul 13.

21.

Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and neck squamous-cell carcinoma, and gastro-oesophageal adenocarcinoma: a five-arm phase 2 study.

Melichar B, Adenis A, Lockhart AC, Bennouna J, Dees EC, Kayaleh O, Obermannova R, DeMichele A, Zatloukal P, Zhang B, Ullmann CD, Schusterbauer C.

Lancet Oncol. 2015 Apr;16(4):395-405. doi: 10.1016/S1470-2045(15)70051-3. Epub 2015 Feb 27.

PMID:
25728526
22.

A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors.

Soliman HH, Jackson E, Neuger T, Dees EC, Harvey RD, Han H, Ismail-Khan R, Minton S, Vahanian NN, Link C, Sullivan DM, Antonia S.

Oncotarget. 2014 Sep 30;5(18):8136-46.

23.

Phase I dose-escalation study of LCL161, an oral inhibitor of apoptosis proteins inhibitor, in patients with advanced solid tumors.

Infante JR, Dees EC, Olszanski AJ, Dhuria SV, Sen S, Cameron S, Cohen RB.

J Clin Oncol. 2014 Oct 1;32(28):3103-10. doi: 10.1200/JCO.2013.52.3993. Epub 2014 Aug 11.

PMID:
25113756
24.

A phase I trial of everolimus in combination with 5-FU/LV, mFOLFOX6 and mFOLFOX6 plus panitumumab in patients with refractory solid tumors.

McRee AJ, Davies JM, Sanoff HG, Goldberg RM, Bernard S, Dees EC, Keller K, Ivanova A, O'Neil BH.

Cancer Chemother Pharmacol. 2014 Jul;74(1):117-23. doi: 10.1007/s00280-014-2474-0. Epub 2014 May 13.

25.

Genetic heterogeneity beyond CYP2C8*3 does not explain differential sensitivity to paclitaxel-induced neuropathy.

Hertz DL, Roy S, Jack J, Motsinger-Reif AA, Drobish A, Clark LS, Carey LA, Dees EC, McLeod HL.

Breast Cancer Res Treat. 2014 May;145(1):245-54. doi: 10.1007/s10549-014-2910-1. Epub 2014 Apr 6.

26.

CYP2C8*3 increases risk of neuropathy in breast cancer patients treated with paclitaxel.

Hertz DL, Roy S, Motsinger-Reif AA, Drobish A, Clark LS, McLeod HL, Carey LA, Dees EC.

Ann Oncol. 2013 Jun;24(6):1472-8. doi: 10.1093/annonc/mdt018. Epub 2013 Feb 14.

27.

Improving endocrine therapy for breast cancer: it's not that simple.

Dees EC, Carey LA.

J Clin Oncol. 2013 Jan 10;31(2):171-3. doi: 10.1200/JCO.2012.46.2655. Epub 2012 Dec 10. No abstract available.

PMID:
23233714
28.

Phase II open-label study of sunitinib in patients with advanced breast cancer.

Yardley DA, Dees EC, Myers SD, Li S, Healey P, Wang Z, Brickman MJ, Paolini J, Kern KA, Citrin DL.

Breast Cancer Res Treat. 2012 Dec;136(3):759-67. doi: 10.1007/s10549-012-2285-0. Epub 2012 Oct 17.

PMID:
23073758
29.

Phase I study and biomarker analysis of lapatinib and concurrent radiation for locally advanced breast cancer.

Kimple RJ, Horton JK, Livasy CA, Shields JM, Lawrence JA, Chiu WM, Ivanova A, Ollila DW, Carey LA, Halle JS, Sartor CI, Dees EC.

Oncologist. 2012;17(12):1496-503. doi: 10.1634/theoncologist.2012-0256. Epub 2012 Sep 24.

30.

Phase I study of aurora A kinase inhibitor MLN8237 in advanced solid tumors: safety, pharmacokinetics, pharmacodynamics, and bioavailability of two oral formulations.

Dees EC, Cohen RB, von Mehren M, Stinchcombe TE, Liu H, Venkatakrishnan K, Manfredi M, Fingert H, Burris HA 3rd, Infante JR.

Clin Cancer Res. 2012 Sep 1;18(17):4775-84. doi: 10.1158/1078-0432.CCR-12-0589. Epub 2012 Jul 5.

31.

Pilot study of rosiglitazone as an in vivo probe of paclitaxel exposure.

Hertz DL, Walko CM, Bridges AS, Hull JH, Herendeen J, Rollins K, Watkins PB, Dees EC.

Br J Clin Pharmacol. 2012 Jul;74(1):197-200. doi: 10.1111/j.1365-2125.2012.04165.x.

32.

CYP2C8*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel.

Hertz DL, Motsinger-Reif AA, Drobish A, Winham SJ, McLeod HL, Carey LA, Dees EC.

Breast Cancer Res Treat. 2012 Jul;134(1):401-10. doi: 10.1007/s10549-012-2054-0. Epub 2012 Apr 18.

33.

Drug interaction potential of trastuzumab emtansine (T-DM1) combined with pertuzumab in patients with HER2-positive metastatic breast cancer.

Lu D, Burris HA 3rd, Wang B, Dees EC, Cortes J, Joshi A, Gupta M, Yi JH, Chu YW, Shih T, Fang L, Girish S.

Curr Drug Metab. 2012 Sep 1;13(7):911-22.

PMID:
22475266
34.

The effect of aprepitant and race on the pharmacokinetics of cyclophosphamide in breast cancer patients.

Walko CM, Combest AJ, Spasojevic I, Yu AY, Bhushan S, Hull JH, Hoskins J, Armstrong D, Carey L, Collicio F, Dees EC.

Cancer Chemother Pharmacol. 2012 May;69(5):1189-96. doi: 10.1007/s00280-011-1815-5. Epub 2012 Jan 15.

PMID:
22245954
35.

Taxane doublets for metastatic breast cancer: do we need another cytotoxic pair or another approach?

Dees EC.

J Clin Oncol. 2011 Dec 20;29(36):4738-40. doi: 10.1200/JCO.2011.38.1327. Epub 2011 Nov 14. No abstract available.

PMID:
22084370
36.

Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study.

Irvin WJ Jr, Walko CM, Weck KE, Ibrahim JG, Chiu WK, Dees EC, Moore SG, Olajide OA, Graham ML, Canale ST, Raab RE, Corso SW, Peppercorn JM, Anderson SM, Friedman KJ, Ogburn ET, Desta Z, Flockhart DA, McLeod HL, Evans JP, Carey LA.

J Clin Oncol. 2011 Aug 20;29(24):3232-9. doi: 10.1200/JCO.2010.31.4427. Epub 2011 Jul 18.

37.

Impact of breast cancer molecular subtypes on locoregional recurrence in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer.

Meyers MO, Klauber-Demore N, Ollila DW, Amos KD, Moore DT, Drobish AA, Burrows EM, Dees EC, Carey LA.

Ann Surg Oncol. 2011 Oct;18(10):2851-7. doi: 10.1245/s10434-011-1665-8. Epub 2011 Mar 26.

PMID:
21442348
38.

Phase I assessment of new mechanism-based pharmacodynamic biomarkers for MLN8054, a small-molecule inhibitor of Aurora A kinase.

Chakravarty A, Shinde V, Tabernero J, Cervantes A, Cohen RB, Dees EC, Burris H, Infante JR, Macarulla T, Elez E, Andreu J, Rodriguez-Braun E, Rosello S, von Mehren M, Meropol NJ, Langer CJ, ONeil B, Bowman D, Zhang M, Danaee H, Faron-Yowe L, Gray G, Liu H, Pappas J, Silverman L, Simpson C, Stringer B, Tirrell S, Veiby OP, Venkatakrishnan K, Galvin K, Manfredi M, Ecsedy JA.

Cancer Res. 2011 Feb 1;71(3):675-85. doi: 10.1158/0008-5472.CAN-10-1030. Epub 2010 Dec 10.

39.

Phase II study of bortezomib and pegylated liposomal doxorubicin in the treatment of metastatic breast cancer.

Irvin WJ Jr, Orlowski RZ, Chiu WK, Carey LA, Collichio FA, Bernard PS, Stijleman IJ, Perou C, Ivanova A, Dees EC.

Clin Breast Cancer. 2010 Dec 1;10(6):465-70. doi: 10.3816/CBC.2010.n.061.

40.

The warfarin-cranberry juice interaction revisited: A systematic in vitro-in vivo evaluation.

Ngo N, Brantley SJ, Carrizosa DR, Kashuba AD, Dees EC, Kroll DJ, Oberlies NH, Paine MF.

J Exp Pharmacol. 2010 Jul;2010(2):83-91.

41.

Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors.

Dees EC, Infante JR, Cohen RB, O'Neil BH, Jones S, von Mehren M, Danaee H, Lee Y, Ecsedy J, Manfredi M, Galvin K, Stringer B, Liu H, Eton O, Fingert H, Burris H.

Cancer Chemother Pharmacol. 2011 Apr;67(4):945-54. doi: 10.1007/s00280-010-1377-y. Epub 2010 Jul 7.

42.

A phase I trial of sorafenib combined with cisplatin/etoposide or carboplatin/pemetrexed in refractory solid tumor patients.

Davies JM, Dhruva NS, Walko CM, Socinski MA, Bernard S, Hayes DN, Kim WY, Ivanova A, Keller K, Hilbun LR, Chiu M, Dees EC, Stinchcombe TE.

Lung Cancer. 2011 Feb;71(2):151-5. doi: 10.1016/j.lungcan.2010.05.022. Epub 2010 Jul 1.

43.

A phase I evaluation of the combination of vinflunine and erlotinib in patients with refractory solid tumors.

Sanoff HK, Davies JM, Walko C, Irvin W, Buie L, Keller K, Ivanova A, Chiu WK, O'Neil BH, Stinchcombe TE, Dees EC.

Invest New Drugs. 2011 Oct;29(5):978-83. doi: 10.1007/s10637-010-9427-1. Epub 2010 Apr 13.

44.

Phase I trial of vinflunine and pemetrexed in refractory solid tumors.

Sanoff HK, Davies J, Walko C, Buie L, Chiu WK, Ivanova A, O'Neil B, Stinchcombe TE, Keller K, Dees EC.

Invest New Drugs. 2011 Feb;29(1):131-6. doi: 10.1007/s10637-009-9344-3. Epub 2009 Oct 15.

45.

Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301.

Miller AA, Murry DJ, Owzar K, Hollis DR, Kennedy EB, Abou-Alfa G, Desai A, Hwang J, Villalona-Calero MA, Dees EC, Lewis LD, Fakih MG, Edelman MJ, Millard F, Frank RC, Hohl RJ, Ratain MJ.

J Clin Oncol. 2009 Apr 10;27(11):1800-5. doi: 10.1200/JCO.2008.20.0931. Epub 2009 Mar 2.

46.

Identification of a cranberry juice product that inhibits enteric CYP3A-mediated first-pass metabolism in humans.

Ngo N, Yan Z, Graf TN, Carrizosa DR, Kashuba AD, Dees EC, Oberlies NH, Paine MF.

Drug Metab Dispos. 2009 Mar;37(3):514-22. doi: 10.1124/dmd.108.024968. Epub 2008 Dec 29.

47.

Quantifying the recruitment challenges with couple-based interventions for cancer: applications to early-stage breast cancer.

Fredman SJ, Baucom DH, Gremore TM, Castellani AM, Kallman TA, Porter LS, Kirby JS, Dees EC, Klauber-Demore N, Peppercorn J, Carey LA.

Psychooncology. 2009 Jun;18(6):667-73. doi: 10.1002/pon.1477.

48.

Perceptions and management approaches of physicians who care for women with ductal carcinoma in situ.

Partridge A, Winer JP, Golshan M, Bellon JR, Blood E, Dees EC, Sampson E, Emmons KM, Winer E.

Clin Breast Cancer. 2008 Jun;8(3):275-80. doi: 10.3816/CBC.2008.n.032.

PMID:
18650159
49.

Phase I trial of nanoparticle albumin-bound paclitaxel in combination with gemcitabine in patients with thoracic malignancies.

Stinchcombe TE, Socinski MA, Lee CB, Hayes DN, Moore DT, Goldberg RM, Dees EC.

J Thorac Oncol. 2008 May;3(5):521-6. doi: 10.1097/JTO.0b013e31816de2a7.

50.

A phase I and pharmacologic study of the combination of bortezomib and pegylated liposomal doxorubicin in patients with refractory solid tumors.

Dees EC, O'Neil BH, Lindley CM, Collichio F, Carey LA, Collins J, Riordan WJ, Ivanova A, Esseltine D, Orlowski RZ.

Cancer Chemother Pharmacol. 2008 Dec;63(1):99-107. doi: 10.1007/s00280-008-0716-8. Epub 2008 Mar 8.

Supplemental Content

Support Center